Loading clinical trials...
Loading clinical trials...
Therapeutic agents used in malignant melanoma treatment such as BRAF/MEK inhibitors and anti-CTLA-4/Anti-PD-1 antibodies go along with harmful side effects in a considerable proportion of patients and...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
University Hospital Tuebingen
NCT03166397 · Malignant Melanoma Stage IV
NCT03493230 · Malignant Melanoma Stage IV, Malignant Melanoma Stage III
NCT01676779 · Malignant Melanoma Stage III, Malignant Melanoma Stage IV
NCT01983124 · Malignant Melanoma Stage IV
NCT00722098 · Malignant Melanoma Stage IV
Dept. of Radiology, University of Tuebingen
Tübingen
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions